CJC-1295 with DAC
LIMITED EVIDENCEAlso known as: CJC-1295 DAC, Drug Affinity Complex GHRH analogue
Investigational — not approved for human use
Educational Overview
A GHRH analogue incorporating a drug affinity complex that substantially extends its half-life compared with the non-DAC form.
Research Mechanism
Binds albumin via the DAC moiety, prolonging exposure. Studied in research settings for sustained GH-axis signalling.
Areas of Study
- GH-axis signalling (preclinical)
- Half-life extension research
Safety Considerations
Human safety is not established. The extended half-life means exposure cannot be quickly reversed. Research material only.
Frequently Asked Questions
Is this approved for human use?
No. This material is supplied for laboratory research use only by qualified businesses and institutions. It is not a medicine and is not for human or veterinary consumption.
How do I get pricing?
Request a quote and our team will respond with current pricing and available sizes for your account.
Do you provide purity documentation?
Certificates of analysis are available to approved accounts. Contact our team for batch-specific documentation.
References
References pending editorial review
We publish citations only after a qualified reviewer has verified them against the primary literature. We do not list references we have not checked. (1 queued.)
Last reviewed: 2026-07-23 · Status: in_review · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.